Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024:2805:89-100.
doi: 10.1007/978-1-0716-3854-5_5.

Engineered Heart Tissues for Standard 96-Well Tissue Culture Plates

Alex J Goldstein  1   2   3 , Ruby M Padgett  2   3   4 , Samantha B Bremner  2   3   5 , Ty Higashi  2   3   4 , Ava M Obenaus  2   3   4 , Sam Bolduan  4 , David L Mack  2   3   5   6 , Nathan J Sniadecki  7   8   9   10   11
Affiliations

Engineered Heart Tissues for Standard 96-Well Tissue Culture Plates

Alex J Goldstein et al. Methods Mol Biol. 2024.

Abstract

Engineered heart tissues (EHTs) have been shown to be a valuable platform for disease investigation and therapeutic testing by increasing human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) maturity and better recreating the native cardiac environment. The protocol detailed in this chapter describes the generation of miniaturized EHTs (mEHTs) incorporating hiPSC-CMs and human stromal cells in a fibrin hydrogel. This platform utilizes an array of silicone posts designed to fit in a standard 96-well tissue culture plate. Stromal cells and hiPSC-CMs are cast in a fibrin matrix suspended between two silicone posts, forming an mEHT that produces synchronous muscle contractions. The platform presented here has the potential to be used for high throughput characterization and screening of disease phenotypes and novel therapeutics through measurements of the myocardial function, including contractile force and calcium handling, and its compatibility with immunostaining.

Keywords: Cardiac therapies; Cardiac tissue engineering; Cardiomyocytes; Engineered heart tissue; Induced pluripotent stem cells.

PubMed Disclaimer

References

    1. Ottaviani D, Ter Huurne M, Elliott DA, Bellin M, Mummery CL (2023) Maturing differentiated human pluripotent stem cells in vitro: methods and challenges. Development 150(11). https://doi.org/10.1242/dev.201103
    1. Hoes MF, Bomer N, van der Meer P (2019) Concise review: the current state of human in vitro cardiac disease modeling: a focus on gene editing and tissue engineering. Stem Cells Transl Med 8(1):66–74. https://doi.org/10.1002/sctm.18-0052 - DOI - PubMed
    1. Pioner JM, Fornaro A, Coppini R et al (2020) Advances in stem cell modeling of dystrophin-associated disease: implications for the wider world of dilated cardiomyopathy. Front Physiol 11. https://doi.org/10.3389/fphys.2020.00368
    1. Savoji H, Mohammadi MH, Rafatian N et al (2019) Cardiovascular disease models: a game changing paradigm in drug discovery and screening. Biomaterials 198:3–26. https://doi.org/10.1016/j.biomaterials.2018.09.036 - DOI - PubMed
    1. Das SL, Sutherland BP, Lejeune E, Eyckmans J, Chen CS (2022) Mechanical response of cardiac microtissues to acute localized injury. Am J Physiol Heart Circ Physiol 323(4):H738–H748. https://doi.org/10.1152/ajpheart.00305.2022 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources